

Special Issue

Innovative Technology in Vaccine Development: Advancing Immunization Strategies

Message from the Guest Editor

Recent advancements in innovative technologies have transformed vaccine development, allowing for faster, safer, and more effective immunization strategies. Traditional vaccine production methods, such as live-attenuated and inactivated vaccines, have been enhanced and, in some cases, replaced by cutting-edge approaches. For example, mRNA vaccine platforms—demonstrated by the rapid response during the COVID-19 pandemic—offer flexibility, scalability, and precision in antigen expression. Viral vector technologies, nanoparticle-based vaccines, and recombinant protein platforms have improved immunogenicity while ensuring safety. This Special Issue invites original research and review articles on preclinical and clinical advancements in cutting-edge technologies for next-generation vaccines to combat emerging infectious diseases. We also welcome innovative studies that identify novel vaccine targets through advanced computational biology, artificial intelligence, and structural vaccinology, provided they include in vitro and in vivo validation experiments.

Guest Editor

Dr. Aziz Chentoufi

Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, CA 92697, USA

Deadline for manuscript submissions

31 December 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/232730

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).